阿仑膦酸钠治疗绝经后骨质疏松症的临床疗效观察

Clinical observation of alendronate sodium in the treatment of postmenopausal osteoporosis

目的分析阿仑膦酸钠治疗绝经后骨质疏松症的临床疗效。方法94例绝经后骨质疏松症患者,随机分为观察组和对照组,每组47例。对照组患者给予阿法骨化醇联合钙尔奇进行治疗,观察组患者在对照组基础上给予阿仑膦酸钠进行治疗。比较两组患者治疗效果、治疗前后骨代谢和骨密度、不良反应发生情况。结果观察组患者治疗总有效率为95.47%,高于对照组的80.85%,差异具有统计学意义(P<0.05)。治疗前,两组患者骨钙素(BGP)、Ⅰ型胶原N末端肽(NTX)、碱性磷酸酶(ALP)水平及L1~4、左侧髋骨骨密度比较差异无统计学意义(P>0.05);治疗后,观察组患者BGP、NTX、ALP水平及L1~4、左侧髋骨骨密度分别为(9.81±0.94)μg/L、(85±4)nmol/L、(60±5)U/L、(0.93±0.09)g/cm^2、(0.84±0.12)g/cm^2,均优于对照组的(8.11±0.81)μg/L、(90±4)nmol/L、(66±5)U/L、(0.84±0.10)g/cm^2、(0.77±0.14)g/cm^2,差异具有统计学意义(P<0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论阿仑膦酸钠治疗绝经后骨质疏松症能够显著提高患者的临床治疗效果,并能够显著改善患者的骨代谢和骨密度情况,且不会增加患者的不良反应,治疗安全性高。

Objective To analyze the clinical efficacy of alendronate sodium in the treatment of postmenopausal osteoporosis.Methods A total of 94 patients with postmenopausal osteoporosis were randomly divided into observation group and control group,with 47 cases in each group.The control group was treated with alfacalcidol combined with Caltrate,and the observation group was treated with alendronate sodium on the basis of the control group.The therapeutic effect,bone metabolism and bone mineral density before and after treatment and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of treatment of the observation group was 95.47%,which was higher than that of the control group 80.85%,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in bone gla protein(BGP),N-terminal typeⅠcollagen telopeptide(NTX),alkaline phosphatase(ALP)levels and L1-4 and left hip bone mineral density between the two groups(P>0.05).After treatment,BGP,NTX,ALP level and L1-4 and left hip bone mineral density of the observation group were(9.81±0.94)μg/L,(85±4)nmol/L,(60±5)U/L,(0.93±0.09)g/cm^2 and(0.84±0.12)g/cm^2,which were all better than those of the control group(8.11±0.81)μg/L,(90±4)nmol/L,(66±5)U/L,(0.84±0.10)g/cm^2 and(0.77±0.14)g/cm^2,and the difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of adverse reactions between the two groups(P>0.05).Conclusion For the treatment of postmenopausal osteoporosis,alendronate sodium can significantly improve the clinical effect of patients,as well as the bone metabolism and bone density without increase of adverse reactions,and the treatment is highly safe.